In corneal refractive surgery, corneal topography is used preoperatively to detect irregular astigmatism, ectatic corneal disorders, or other abnormalities, and to monitor topographic stability ...

Background/Aims To investigate the efficacy of therapeutic soft contact lenses (SCLs) in gelatinous drop-like corneal dystrophy (GDLD) management. Methods This was a retrospective, consecutive, ...

Keywords: eye-rubbing, keratoconus, cornea, ectasia, corneal topography, progression Citation: Mazharian A, Flamant R, Elahi S, Panthier C, Rampat R and Gatinel D (2023) Medium to long term follow up ...

Genetics Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the DMD gene—located on the X chromosome and representing the largest known human gene with 2.4 million base ...

Corneal Endothelial Dystrophy Pipeline constitutes 4+ key companies continuously working towards developing 4+ Corneal Endothelial Dystrophy treatment therapies, analyzes DelveInsight.

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases Capricor remains on track for the ...

The one-time treatment is approved for children with a genetic variant of Duchenne’s muscular dystrophy, which causes weakness, loss of mobility and early death in males. Elevidys is the first gene ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported ...

Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the death over the ...

Second death linked to Sarepta Therapeutics treatment leaves Duchenne muscular dystrophy community reeling, Elevidys use halted in non-ambulatory patients.

Biotech pauses trial after second patient death linked to gene therapy Sarepta Therapeutics said it would temporarily stop shipping treatments for certain Duchenne muscular dystrophy patients.